Comparative Pharmacology
Head-to-head clinical analysis: DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE versus PROMETHAZINE W DEXTROMETHORPHAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE versus PROMETHAZINE W DEXTROMETHORPHAN.
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE vs PROMETHAZINE W/ DEXTROMETHORPHAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine H1 receptors; centrally acting anticholinergic agent that inhibits acetylcholine muscarinic receptors.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist and antiemetic; dextromethorphan is a non-opioid antitussive that acts as an NMDA receptor antagonist and sigma-1 receptor agonist.
25 to 50 mg intravenously or intramuscularly every 4 to 6 hours as needed; maximum 400 mg per day.
5 mL (containing promethazine 6.25 mg and dextromethorphan 15 mg) orally every 4-6 hours as needed, not to exceed 30 mL (promethazine 37.5 mg, dextromethorphan 90 mg) per 24 hours.
None Documented
None Documented
Terminal elimination half-life: 4-10 hours (mean ~8 hours); prolonged in hepatic impairment or elderly (up to 20 hours).
Promethazine: 9-16 h; dextromethorphan: 3-5 h (extensive metabolizers), 30-50 h (poor metabolizers). Clinical context: dosing interval typically 4-6 h for dextromethorphan; promethazine accumulates with repeated dosing.
Primarily renal as inactive metabolites; ~60% of a dose appears in urine as metabolites, with <5% unchanged. Minor biliary/fecal elimination (<10%).
Renal: promethazine ~6% unchanged, dextromethorphan ~0.5% unchanged; metabolites primarily renal. Biliary/fecal: minor routes for both.
Category A/B
Category A/B
Antihistamine
Antihistamine / Antiemetic